A cash position of 15.2 million euros on December 31, 2021, strengthened to 28 million euros on March 28, 2022 Major technical advances in 2021: - The approval to enter Phase 3 in China for
Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")
These clinical studies conducted in Germany will contribute to the dossier for phase 3 studies in China BioChaperone Combo targets the premix insulin market, which accounts for 65% of insulin
AMANDA PLATELL:. A mega-bag slung over one shoulder, fashionistas have long held, will render women thinner and even taller, covering a multitude of sins.
The Company announces the sale of its building in Lyon in a sale and leaseback transaction worth over 20 million euros This transaction results in a net cash inflow of 19 million euros and